CVKD - Cadrenal Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Cadrenal Therapeutics, Inc.

822 A1A North
Suite 306
Ponte Vedra, FL 32082
United States
904 300 0701

Full-time employees3

Key executives

NameTitlePayExercisedYear born
Mr. Quang X. PhamChairman & CEO822.17kN/A1965
Mr. Matthew K. Szot CPA, CPACo-Founder & CFO359.61kN/A1974
Dr. Douglas W. Losordo FACC, FAHA, M.D.Chief Medical Officer23.36kN/A1958
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Corporate governance

Cadrenal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.